Sarepta Therapeutics, Inc. Contracts & Agreements

Supplement to Goldman Sachs & Co. LLC Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation (Filed With SEC on November 6, 2024)

Supplement to JPMorgan Chase Bank, National Association Base Capped Call Option Transaction Confirmation and Additional Capped Call Option Transaction Confirmation (Filed With SEC on November 6, 2024)

Amendment No. 1 to the Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan (Filed With SEC on June 7, 2024)

Form of Stock Option Award Agreement under Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan (Filed With SEC on May 1, 2024)

Form of Restricted Stock Unit Award Agreement under Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan (Filed With SEC on May 1, 2024)

Amendment no. 11 dated June 23, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on February 28, 2024)

Amendment no. 12 dated July 28, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on February 28, 2024)

Amendment no. 13 dated August 31, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on February 28, 2024)

Amendment no. 14 dated October 31, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on February 28, 2024)

Sarepta Therapeutics Inc.'s Policy for Recoupment of Incentive Compensation (Filed With SEC on February 28, 2024)

Amendment No. 3 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on June 9, 2023)

Amendment No. 2 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (Filed With SEC on June 9, 2023)

Form of Exchange Agreement (Filed With SEC on March 3, 2023)

Indenture, dated as of September 16, 2022, by and between Sarepta Therapeutics, Inc. and U. S. Bank Trust Company, National Association (including the form of the 1.250%... (Filed With SEC on September 19, 2022)

Purchase Agreement, dated as of September 13, 2022, among Sarepta Therapeutics, Inc. and the several Initial Purchasers named in Schedule 1 thereto for whom Goldman, Sachs & Co.... (Filed With SEC on September 19, 2022)

Purchase Agreement, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Michael A. Chambers Living Trust (Filed With SEC on September 19, 2022)

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Barclays Bank PLC (Filed With SEC on September 19, 2022)

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on September 19, 2022)

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Mizuho Markets Americas LLC (Filed With SEC on September 19, 2022)

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and Morgan Stanley & Co. LLC (Filed With SEC on September 19, 2022)

Base Call Option Transaction Confirmation, dated as of September 13, 2022, between Sarepta Therapeutics, Inc. and RBC Capital Markets, LLC (Filed With SEC on September 19, 2022)

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and Barclays Bank PLC (Filed With SEC on September 19, 2022)

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on September 19, 2022)

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and Mizuho Markets Americas LLC (Filed With SEC on September 19, 2022)

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and Morgan Stanley & Co. LLC (Filed With SEC on September 19, 2022)

Additional Call Option Transaction Confirmation, dated as of September 14, 2022 between Sarepta Therapeutics, Inc. and RBC Capital markets, LLC (Filed With SEC on September 19, 2022)

Amendment no. 9 dated March 23, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on August 2, 2022)

Amendment No. 2 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on June 3, 2022)

Form of Performance-Based Restricted Stock Unit Award Agreement under Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on May 4, 2022)

Letter Agreement, dated April 19, 2022, between Sarepta Therapeutics, Inc. and Douglas S. Ingram (Filed With SEC on April 21, 2022)

Amendment no. 6 dated November 30, 2021 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on March 1, 2022)

Amendment no. 7 dated January 5, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on March 1, 2022)

Amendment no. 8 dated January 28, 2022 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on March 1, 2022)

Separation Agreement and General Release, signed November 15, 2021 between Sarepta Therapeutics, Inc. and Dr. Gilmore O'Neill (Filed With SEC on March 1, 2022)

Amendment No. 2, dated November 17, 2021 to License Agreement between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc. on the one hand and BioMarin Leiden... (Filed With SEC on March 1, 2022)

Amendment no. 5 dated August 31, 2021 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd dated December 21,... (Filed With SEC on November 3, 2021)

Underwriting Agreement, October 13, 2021 among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Credit Suisse... (Filed With SEC on October 15, 2021)

Amendment no. 1 dated October 23, 2020 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd dated December 21,... (Filed With SEC on August 4, 2021)

Amendment no. 2 dated October 28, 2020 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on August 4, 2021)

Amendment no. 3 dated February 4, 2021 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21,... (Filed With SEC on August 4, 2021)

Amendment no. 4 dated June 23, 2021 to the License, Collaboration, and Option Agreement between Sarepta Therapeutics Three, LLC and F. Hoffman-La Roche Ltd, dated December 21, 2019 (Filed With SEC on August 4, 2021)

Separation and Consulting Agreement and General Release between David T. Howton Jr. and Sarepta Therapeutics, Inc (Filed With SEC on March 1, 2021)

Promotion Letter dated December 14, 2020 by and between Sarepta Therapeutics, Inc. and Louise Rodino-Klapac (Filed With SEC on March 1, 2021)

Offer Letter dated April 19, 2018 by and between Sarepta Therapeutics, Inc. and Louise Rodino-Klapac (Filed With SEC on March 1, 2021)

Promotion Letter dated December 14, 2020 by and between Sarepta Therapeutics, Inc. and Ian M. Estepan (Filed With SEC on March 1, 2021)

Offer Letter dated by December 18, 2014 and between Sarepta Therapeutics, Inc. and Ian M. Estepan (Filed With SEC on March 1, 2021)

Offer Letter dated March 17, 2017 by and between Sarepta Therapeutics, Inc. and Joseph Bratica (Filed With SEC on March 1, 2021)

First Amendment dated September 24, 2020 to Loan Agreement among Sarepta Therapeutics, Inc., BioPharma Credit PLC and BioPharma Credit Investments V (Master) LP dated December 13,... (Filed With SEC on November 5, 2020)

Separation Agreement and General Release between Sandesh Mahatme and Sarepta Therapeutics, Inc (Filed With SEC on August 5, 2020)

Amendment No. 1 to the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on June 8, 2020)

Description of Registered Securities (Filed With SEC on February 26, 2020)

Amendment No. 2 to the Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan (Filed With SEC on February 21, 2020)

Amendment No. 1 to License Agreement between Sarepta Therapeutics, Inc. and ST International Holdings Two, Inc. on the one hand and BioMarin Leiden Holding BV, BioMarin Nederlands... (Filed With SEC on August 7, 2019)

Sub-Plan for Japan under the Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on August 7, 2019)

Sub-Plan for Japan under the Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan (Filed With SEC on August 7, 2019)

Amendment No. 1 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employment Stock Purchase Plan (as Amended and Restated on June 27, 2016) (Filed With SEC on August 7, 2019)

Letter Agreement between Sarepta Therapeutics, Inc. and Myonexus Therapeutics, Inc. dated February 26, 2019 (Filed With SEC on May 8, 2019)

Form of Severance Letter Agreement entered into between Sarepta Therapeutics, Inc. and each of Sandesh Mahatme, David Tyronne Howton, Jr. and Alexander Bo Cumbo (Filed With SEC on May 8, 2019)

Form of Change in Control and Severance Agreement entered into between Sarepta Therapeutics, Inc. and each of Sandesh Mahatme, David Tyronne Howton, Jr. and Alexander Bo Cumbo (Filed With SEC on May 8, 2019)

Underwriting Agreement, March 5, 2019 among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, as representatives of the underwriters named... (Filed With SEC on March 7, 2019)

Amendment to Restricted Stock Award Agreement between Douglas S. Ingram and Sarepta Therapeutics, Inc. dated December 17, 2018 (Filed With SEC on February 28, 2019)

Underwriting Agreement, dated November 8, 2018, among Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC, as... (Filed With SEC on November 9, 2018)

Form of Stock Option Award Agreement under Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on October 31, 2018)

Form of Restricted Stock Award Agreement under Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on October 31, 2018)

Form of Restricted Stock Unit Award Agreement under Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on October 31, 2018)

Form of Stock Appreciation Right Award Agreement under Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on October 31, 2018)

Warrant to Purchase Common Stock of Myonexus Therapeutics, Inc., issued by Myonexus Therapeutics, Inc. to Sarepta Therapeutics, Inc., dated as of May 3, 2018 (Filed With SEC on August 8, 2018)

Sarepta Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on August 8, 2018)

Employment Agreement between Sarepta Therapeutics, Inc. and Gilmore ONeill, M.D., effective as of June 7, 2018 (Filed With SEC on August 8, 2018)

Change in Control and Severance Agreement between Sarepta Therapeutics, Inc. and Gilmore ONeill, M.D., effective as of June 7, 2018 (Filed With SEC on August 8, 2018)

Letter Agreement between Douglas S. Ingram and Sarepta Therapeutics, Inc. dated June 26, 2018 (Filed With SEC on August 8, 2018)

Form of Restricted Stock Unit Award Agreement under Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan (Filed With SEC on August 8, 2018)

Amendment No. 2 to the Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan (Filed With SEC on August 8, 2018)

General Release and Amendment to Separation Agreement between Sarepta Therapeutics, Inc. and Dr. Catherine Stehman-Breen dated April 12, 2018 (Filed With SEC on May 3, 2018)

Sponsored Research Agreement between AVI BioPharma, Inc. and Charleys Fund, Inc., effective October 12, 2007 (Filed With SEC on May 3, 2018)

First Amendment to Sponsored Research Agreement between AVI BioPharma, Inc. and Charleys Fund, Inc. dated June 2, 2009 (Filed With SEC on May 3, 2018)

Seventh Amendment to a Lease Agreement between the Company and ARE-MA Region No. 38, LLC dated April 27, 2018 (Filed With SEC on May 3, 2018)

Form of Severance Letter Agreement entered between Sarepta Therapeutics, Inc. and each of Sandesh Mahatme, Alexander Bo Cumbo, David Tyronne Howton, Jr. and Shamim Ruff (Filed With SEC on March 1, 2018)

Purchase Agreement, dated as of November 8, 2017, among Sarepta Therapeutics, Inc. and the several Initial Purchasers named in Schedule 1 thereto for whom J.P. Morgan Securities... (Filed With SEC on November 14, 2017)

Indenture, dated as of November 14, 2017, by and between Sarepta Therapeutics, Inc. and U. S. Bank National Association (including the form of the 1.50% Convertible Senior Note... (Filed With SEC on November 14, 2017)

First Amendment to the Amended and Restated Credit and Security Agreement, dated November 7, 2017, between the Company and MidCap Financial Trust, as administrative agent (Filed With SEC on November 14, 2017)

First Amendment to the Credit and Security Agreement, dated November 7, 2017, between the Company and MidCap Financial Trust, as administrative agent (Filed With SEC on November 14, 2017)

Base Call Option Transaction Confirmation, dated as of November 8, 2017, between Sarepta Therapeutics, Inc. and JPMorgan Chase Bank, National Association, London Branch (Filed With SEC on November 14, 2017)

Base Call Option Transaction Confirmation, dated as of November 8, 2017, between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on November 14, 2017)

Additional Call Option Transaction Confirmation, dated as of November 9, 2017, between Sarepta Therapeutics, Inc. and JPMorgan Chase Bank, National Association, London Branch (Filed With SEC on November 14, 2017)

Additional Call Option Transaction Confirmation, dated as of November 9, 2017, between Sarepta Therapeutics, Inc. and Goldman Sachs & Co. LLC (Filed With SEC on November 14, 2017)

Consulting Agreement dated August 17, 2017 by and between Sarepta Therapeutics, Inc. and Dr. Edward M. Kaye (Filed With SEC on November 1, 2017)

Offer Letter dated August 28, 2017 by and between Sarepta Therapeutics, Inc. and Guriqbal S. Basi (Filed With SEC on November 1, 2017)

Letter Agreement by and between Sarepta Therapeutics, Inc. and Guriqbal S. Basi dated September 25, 2017 (Filed With SEC on November 1, 2017)

Letter Agreement by and between Sarepta Therapeutics, Inc. and Catherine Stehman-Breen dated September 26, 2017 (Filed With SEC on November 1, 2017)

Amendment No. 1 to the License and Collaboration Agreement between Summit (Oxford) Ltd. and Sarepta Therapeutics Inc. dated June 13, 2017 (Filed With SEC on August 3, 2017)

Settlement Agreement between Sarepta Therapeutics, Inc., Sarepta International C.V. and The University of Western Australia on the one hand, and BioMarin Leiden Holding BV,... (Filed With SEC on August 3, 2017)

License Agreement between Sarepta Therapeutics, Inc. and Sarepta International C.V. on the one hand and BioMarin Leiden Holding BV, BioMarin Nederlands BV and BioMarin... (Filed With SEC on August 3, 2017)

Amended and Restated Credit and Security Agreement between Sarepta Therapeutics, Inc. and MidCap Financial Trust dated July 18, 2017 (Filed With SEC on August 3, 2017)

7,650,000 Shares SareptaTherapeutics, Inc. Common Stock ($0.0001 par value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on July 26, 2017)

Sarepta Therapeutics, Inc. EMPLOYMENT AGREEMENT (Filed With SEC on June 28, 2017)

SAREPTA THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT (Filed With SEC on June 28, 2017)

AMENDMENT NO. 1 TO THE SAREPTA THERAPEUTICS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN (Filed With SEC on June 28, 2017)

SAREPTA THERAPEUTICS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN RESTRICTED STOCK AGREEMENT (Filed With SEC on June 28, 2017)

SAREPTA THERAPEUTICS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN PERFORMANCE STOCK OPTION AWARD AGREEMENT (Filed With SEC on June 28, 2017)

Asset Purchase Agreement dated February 20, 2017 by and between Sarepta Therapeutics Inc. and Gilead Sciences, Inc (Filed With SEC on May 4, 2017)

Offer Letter dated December 5, 2012 by and between Sarepta Therapeutics, Inc. and Shamim Ruff (Filed With SEC on May 4, 2017)

Offer Letter dated December 3, 2012 by and between Sarepta Therapeutics, Inc. and Alexander Bo Cumbo (Filed With SEC on May 4, 2017)

Offer Letter dated February 2, 2017 by and between Sarepta Therapeutics, Inc. and Dr. Catherine Stehman-Breen (Filed With SEC on May 4, 2017)

SAREPTA THERAPEUTICS, INC. Amended and Restated 2011 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT (Filed With SEC on February 28, 2017)

SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2011 EQUITY INCENTIVE PLAN Restricted Stock Agreement (Filed With SEC on February 28, 2017)

SAREPTA THERAPEUTICS, INC. 2011 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on February 28, 2017)

SAREPTA THERAPEUTICS, INC. Amended and Restated 2011 EQUITY INCENTIVE PLAN STOCK APPRECIATION RIGHT AWARD AGREEMENT (STOCK SETTLED) (Filed With SEC on February 28, 2017)

Sarepta Therapeutics, Inc. EMPLOYMENT AGREEMENT (Filed With SEC on November 7, 2016)

5,020,921 Shares SareptaTherapeutics, Inc. Common Stock ($0.0001 par value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on September 23, 2016)

[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. (Filed With SEC on August 9, 2016)

AMENDED AND RESTATED SAREPTA THERAPEUTICS, INC. 2011 EQUITY INCENTIVE PLAN (as Amended and Restated on June 27, 2016) (Filed With SEC on July 1, 2016)

SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2013 EMPLOYEE STOCK PURCHASE PLAN (as Amended and Restated on June 27, 2016) Sarepta Therapeutics, Inc., a Delaware corporation... (Filed With SEC on July 1, 2016)

2,102,000 Shares SareptaTherapeutics, Inc. Common Stock ($0.0001 par value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on June 10, 2016)

3,250,000 Shares SareptaTherapeutics, Inc. Common Stock ($0.0001 par value) EQUITYUNDERWRITING AGREEMENT (Filed With SEC on October 6, 2015)

CREDIT ANDSECURITY AGREEMENT (Filed With SEC on August 6, 2015)

PLEDGE AGREEMENT (Filed With SEC on August 6, 2015)

SEPARATION AND CONSULTING AGREEMENT AND GENERAL RELEASE (Filed With SEC on August 6, 2015)

AMENDMENT NO. 1 TO THE SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2011 INCENTIVE PLAN (Filed With SEC on June 30, 2015)

SAREPTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 7, 2015)

PURCHASE AND SALE AGREEMENT (Filed With SEC on August 7, 2014)

2,650,000Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 par value) EQUITY UNDERWRITING AGREEMENT (Filed With SEC on April 24, 2014)

SAREPTA THERAPEUTICS, INC. EXECUTIVE INDUCEMENT STOCK OPTION AWARD AGREEMENT (Filed With SEC on March 3, 2014)

SAREPTA THERAPEUTICS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN (Filed With SEC on March 3, 2014)

SAREPTA THERAPEUTICS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT (Filed With SEC on March 3, 2014)

Signature(s) Guaranteed: Medallion Guarantee Stamp (Filed With SEC on August 8, 2013)

AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 8, 2013)

SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2011 EQUITY INCENTIVEPLAN NOTICE OF GRANT OF RESTRICTED STOCK (Filed With SEC on August 8, 2013)

SAREPTA THERAPEUTICS, INC. AMENDED AND RESTATED 2011 EQUITY INCENTIVEPLAN STOCK OPTION AWARD AGREEMENT (Filed With SEC on August 8, 2013)

SAREPTA THERAPEUTICS, INC. Common Stock ($0.0001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT (Filed With SEC on July 3, 2013)

LEASE AGREEMENT (Filed With SEC on July 1, 2013)

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on May 9, 2013)

SAREPTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 9, 2013)

SAREPTA THERAPEUTICS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT (Filed With SEC on March 15, 2013)

4,950,495 Shares of Common Stock par value $0.0001 742,574 Over-Allotment Shares SAREPTA THERAPEUTICS, INC. UNDERWRITING AGREEMENT (Filed With SEC on December 18, 2012)

15B, SUPPLIES/SERVICES (Filed With SEC on November 7, 2012)

SAREPTA THERAPEUTICS, INC. 2011 EQUITY INCENTIVE PLAN STOCK APPRECIATION RIGHT AWARD AGREEMENT (STOCK SETTLED) (Filed With SEC on November 7, 2012)

SAREPTA THERAPEUTICS, INC. Common Stock ($0.0001 par value per share) AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT (Filed With SEC on September 4, 2012)

THIRD AMENDMENT TO LEASE (Filed With SEC on August 7, 2012)

AVI BIOPHARMA, INC. 2011 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on April 25, 2012)

LEASE AGREEMENT (Filed With SEC on March 13, 2012)

FIRST AMENDMENT TO LEASE AGREEMENT (Filed With SEC on March 13, 2012)

SECOND AMENDMENT TO LEASE AGREEMENT (Filed With SEC on March 13, 2012)

SECOND AMENDMENT TO LEASE (Filed With SEC on March 13, 2012)

SEPARATION AGREEMENT AND RELEASE (Filed With SEC on November 8, 2011)

SEPARATION AND RELEASE AGREEMENT (Filed With SEC on November 8, 2011)

13. THIS ITEM ONLY APPLIES TO MODIFICATION OFCONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. (Filed With SEC on November 8, 2011)

FIRST AMENDMENT TO LEASE (Filed With SEC on November 8, 2011)

3. EFFECTIVE DATE 13-Apr-2011 (Filed With SEC on August 8, 2011)

SEPARATION AND RELEASE AGREEMENT (Filed With SEC on August 8, 2011)

AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 8, 2011)

AVI BIOPHARMA, INC. 2011 EQUITY INCENTIVE PLAN (effective as of shareholder approval at the 2011 annual meeting of shareholders) (Filed With SEC on June 16, 2011)

AVI BIOPHARMA, INC. 2011 EQUITY INCENTIVE PLAN STOCK OPTION AWARD AGREEMENT (Filed With SEC on June 16, 2011)

AVI BIOPHARMA, INC. 2011 EQUITY INCENTIVE PLAN NOTICE OF GRANT OF RESTRICTED STOCK (Filed With SEC on June 16, 2011)

AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2011)

AVI BIOPHARMA, INC. STAND ALONE STOCK OPTION GRANT NOTICE OF GRANT OF STOCK OPTION (Filed With SEC on May 10, 2011)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS (Filed With SEC on May 10, 2011)

AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 10, 2011)

20,000,000 Shares of Common Stock par value $0.0001 3,000,000 Over-Allotment Shares AVI BIOPHARMA, INC. UNDERWRITING AGREEMENT (Filed With SEC on April 1, 2011)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

AVI BIOPHARMA, INC. EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 15, 2011)

3450 MonteVilla Parkway, Suite 101, Bothell, WA 98021 ** 425 ###-###-#### ** FAX: 425 ###-###-#### (Filed With SEC on March 15, 2011)

EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on March 15, 2011)

LEASE EXTENSION AND MODIFICATION AGREEMENT (Filed With SEC on March 15, 2011)

SCHNITZER NORTH CREEK LEASE AGREEMENT S/I NORTH CREEK VII, LLC (Landlord) and AVI BIOPHARMA, INC. (Tenant) Dated: October 20, 2010 (Filed With SEC on March 15, 2011)

AVI BIOPHARMA, INC. FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on October 8, 2010)

AVI BIOPHARMA, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (As adopted September 27, 2010) (Filed With SEC on October 1, 2010)

Defense Threat Reduction Agency (Filed With SEC on August 9, 2010)

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT (Filed With SEC on May 10, 2010)

SETTLEMENTAGREEMENT (Filed With SEC on April 22, 2010)

SEPARATION AND RELEASE AGREEMENT (Filed With SEC on April 22, 2010)

COLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 16, 2010)

LEASE by and between BMR-3450 MONTE VILLA PARKWAY LLC, a Delaware limited liability company and AVI BIOPHARMA, INC., an Oregon corporation (Filed With SEC on November 9, 2009)

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT (Filed With SEC on November 9, 2009)

AVI BioPharma, Inc. UNDERWRITING AGREEMENT (Filed With SEC on August 24, 2009)

COMMON STOCK PURCHASE WARRANT AVI BIOPHARMA, INC. (Filed With SEC on August 24, 2009)

Defense Threat Reduction Agency 8725 John J. Kingman Road, MSC 6201 Fort Belvoir, VA 22060-6201 (Filed With SEC on August 10, 2009)

EMPLOYMENT AGREEMENT (Filed With SEC on August 10, 2009)

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT (Filed With SEC on August 10, 2009)

FIRST AMENDMENT TO SPONSORED RESEARCHAGREEMENT (Filed With SEC on August 10, 2009)

EMPLOYMENTAGREEMENT (Filed With SEC on May 11, 2009)

SEVERANCEAND RELEASE AGREEMENT (Filed With SEC on March 10, 2009)

COMMON STOCK PURCHASE WARRANT AVI BIOPHARMA, INC. (Filed With SEC on January 30, 2009)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on January 30, 2009)

[AVI BioPharma, Inc. letterhead] January 29, 2009 (Filed With SEC on January 30, 2009)

EMPLOYMENT AGREEMENT (Filed With SEC on November 10, 2008)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (Filed With SEC on November 10, 2008)

EMPLOYMENT AGREEMENT (Filed With SEC on August 11, 2008)

AVI BIOPHARMA, INC. EMPLOYMENT AGREEMENT (Filed With SEC on May 12, 2008)

SPONSORED RESEARCH AGREEMENT (Filed With SEC on March 17, 2008)

AGREEMENT dated as of October 29,2007 by and among AVI BioPharma, Inc., AVI Shareholder AdvocacyTrust, The Shareholder AdvocateLLC, and Richard Macary (Filed With SEC on March 17, 2008)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on March 17, 2008)

PROFESSIONALSERVICES AGREEMENT (Filed With SEC on March 17, 2008)

[GHLETTERHEAD] (Filed With SEC on March 17, 2008)

Agreement and Plan of Merger dated March 12,2008 by and among AVI BioPharma, Inc., EB Acquisition Corp., Ercole Biotech, Inc. and the Stockholder Representative (without exhibits). (Filed With SEC on March 13, 2008)

ERCOLE BIOTECH, INC. CONVERTIBLE PROMISSORY NOTE (Filed With SEC on March 13, 2008)

AVI BioPharma, Inc. 10,696,616 Shares Common Stock ($0.0001 par value) and Warrants toPurchase 5,348,308 Sharesof Common Stock Placement Agency Agreement (Filed With SEC on December 13, 2007)

AVI BIOPHARMA, INC. WARRANT TOPURCHASE COMMON STOCK (Filed With SEC on December 13, 2007)

SECONDCOLLABORATION AND LICENSE AGREEMENT (Muscular Dystrophy and Beta Thalassemia) (Filed With SEC on August 9, 2007)

REAL PROPERTYPURCHASE AGREEMENT (Filed With SEC on August 9, 2007)

CROSSLICENSE AGREEMENT between ELEOS,INC. and AVIBIOPHARMA, INC. (Filed With SEC on May 10, 2007)

SEPARATIONAND RELEASE AGREEMENT (Filed With SEC on May 10, 2007)

COLLABORATIONAND LICENSE AGREEMENT (Filed With SEC on March 16, 2007)

SERIES A-2 PREFERRED STOCK AND COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on March 16, 2007)

EXHIBIT10.55 SECONDLEASE EXTENSION AND MODIFICATION AGREEMENT (Filed With SEC on August 9, 2006)

LICENSEAGREEMENT (Filed With SEC on May 10, 2006)

STOCKPURCHASE AGREEMENT (Filed With SEC on May 10, 2006)

COMMON STOCK PURCHASE WARRANT To Purchase 485,920 Shares of Common Stock of AVI BioPharma, Inc. (Filed With SEC on March 16, 2006)

STOCK PURCHASE AGREEMENT (Filed With SEC on March 16, 2006)

STOCK PURCHASE AGREEMENT (Filed With SEC on January 20, 2005)

COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of AVI BioPharma, Inc. (Filed With SEC on January 20, 2005)

Form of 2004 Purchase Warrant AVI BIOPHARMA, INC. WARRANT (Filed With SEC on January 29, 2004)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on December 8, 2003)

[FORM OFADDITIONAL INVESTMENT RIGHT WARRANT] AVIBIOPHARMA, INC. WARRANT (Filed With SEC on December 8, 2003)

[FORM OF PURCHASE WARRANT] AVI BIOPHARMA, INC. WARRANT (Filed With SEC on December 8, 2003)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 9, 2003)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on May 7, 2003)

AVIBIOPHARMA, INC. WARRANT (Filed With SEC on May 7, 2003)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on May 7, 2003)

ADDITIONAL FUNDINGAGREEMENT (Filed With SEC on May 7, 2003)

EMPLOYMENTAGREEMENT (Filed With SEC on August 14, 2001)

OFFICE LEASE (Filed With SEC on August 14, 2001)

INVESTMENTAGREEMENT 1 (Filed With SEC on August 14, 2001)

WARRANT ToPurchase Shares of Common Stock of AVI BIOPHARMA, INC. June20, 2001 (Filed With SEC on August 14, 2001)

REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on August 14, 2001)

LICENSEAND DEVELOPMENT AGREEMENT 1 (Filed With SEC on August 14, 2001)

SUPPLY AGREEMENT 1 (Filed With SEC on August 14, 2001)

Category

Industry

Companies

Contracts

Sarepta Therapeutics, Inc. Contracts & Agreements